Active Pharmaceutical Ingredients
| PRODUCT | CAS NO | THERAPEUTIC CATEGORY | PHARMACOPOEIA | STATUS |
|---|---|---|---|---|
| Phenylephrine Hydrochloride | 61-76-7 | Decongestant | IP/USP/EP | Commercialised(CEP Filed) |
| Dexketoprofen Trometamol | 156604-79-4 | Anti-Inflammatory | In-House | Commercialised(DMF Available) |
| Dapagliflozin Propanediol | 960404-48-2 | Antidiabetic | USP/In-House | Commercialised(DMF Available) |
| Dapagliflozin Amorphous | 461432-26-8 | Antidiabetic | In-House | Commercialised |
| Fexofenadine Hydrochloride | 153439-40-8 | Antihistaminic | IP/USP/EP/JP | Commercialised(CEP Filing in Q3 FY25) |
| Citicoline Sodium | 33818-15-4 | Psychostimulant | IP/USP | Commercialised |
| Ursodeoxycholic Acid | 128-13-2 | Cholelithiasis Agent | IP/USP/EP | Commercialised(DMF available in Q3 FY25) |
| Nicotine | 54-11-5 | Stimulant | Stimulant | Validation in Q3 FY25 |
| Tolvaptan | 150683-30-0 | Diuretic | IP/In-House | Validation in Q3 FY25 |
| Ketoprofen | 22071-15-4 | Anti-Inflammatory | USP/EP | Developed at Lab Scale |
| Tiemonium Methylsulphate | 6504-57-0 | Antispasmodic | IP/In-House | Under development |
| Ticagrelor | 274693-27-5 | Antiplatelet | Under development | |
| Bempedoic Acid | 738606-46-7 | Lipid Lowering Agent | In Pipeline | |
| Vonoprazan Fumarate | 881681-01-2 | Antiulcerative | In Pipeline | |
| Bilastine | 202189-78-4 | Antihistaminic | In Pipeline | |
| Tranexamic Acid | 1197-18-8 | Antifibrinolytic | In Pipeline | |
| Lercanidipine | 100427-26-7 | Antihypertensive | In Pipeline |
Intermediates
| PRODUCT | CAS NO | END API | INTERMEDIATE CODE | STATUS |
|---|---|---|---|---|
| Methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butanoyl)phenyl)-2-methylpropanoate | 154477-55-1 | Fexofenadine Hydrochloride | Fex X/ D10 | Commercialised |
| Phenylephrine Base | 59-42-7 | Phenylephrine Hydrochloride | Commercialised | |
| L-proline benzyl ester hydrochloride | 16652-71-4 | Lisinopril | Commercialised | |
| 3 -Hydroxyacetophenone | 121-71-1 | Commercialisation in Q3 FY24 | ||
| 7-Ethyltryptophol | 41340-36-7 | Etodolac | Under development | |
| Ethyl 7-chloro-2,2-dimethylheptanoate | 2570179-39-2 | Bempedoic Acid | Under development | |
| Diethyl 2,2,14,14-tetramethyl-8-oxopentadecanedioate | 738606-43-4 | Bempedoic Acid | Under development | |
| 2,2,14,14-tetramethyl-8-oxopentadecanedioic acid | 413624-71-2 | Bempedoic Acid | Under development | |
| Phenylacetone | 103-79-7 | In Pipeline | ||
| 2-methyl-4-(2-methyl-benzoylamino)-benzoic acid | 317374-08-6 | Tolvaptan | In Pipeline | |
| 7-Chloro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one | 160129-45-3 | Tolvaptan | In Pipeline | |
| N-(2 -Cyanobiphenyl-4-ylmethyl)-L-valine Methyl Ester Hydrochloride | 482577-59-3 | Valsartan | Developed at Lab Scale | |
| 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone | 32384-65-9 | Dapagliflozin/Empagliflozin | Developed at Lab Scale | |
| 4-Bromo-1-chloro-2-(4-ethoxybenzyl)benzene | 461432-23-5 | Dapagliflozin | DP02 | Developed at Lab Scale |
*Developed products would be commercially available by Q1 2024
**These products are not available for sale in countries where the patents are applicable or still valid